Skip to main content
. 2019 Apr 3;127(5):288–302. doi: 10.1111/apm.12940

Figure 5.

Figure 5

A selection of FDA approved anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in the ATP‐binding site of the ALK kinase domain. The different ALK TKIs (orange) bind in the ATP‐binding pocket with varying contact sites resulting in unique profiles of inhibition of the ALK mutant variants observed in neuroblastoma patients as well as in ALK TKI resistant non‐small cell lung cancer (NSCLC) and inflammatory myofibroblastic tumor (IMT) patients.